A 2-Part Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs JNJ-63733657 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 08 Mar 2018 Planned End Date changed from 30 May 2019 to 4 Jul 2019.
- 09 Feb 2018 Planned End Date changed from 15 Feb 2019 to 30 May 2019.
- 16 Jan 2018 Status changed from not yet recruiting to recruiting.